Physician profile
Daniel Zalkind
NPI 1538315700
$1,650.33
in general payments reported to CMS, 2019-2025
20 companies · $58.46 in 2025
The $58.46 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $167 · 2021: $196 · 2022: $349 · 2023: $207 · 2024: $35.08 · 2025: $58.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268 · Education: $32.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.04 |
| Education | $32.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $268.94 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.73 | 2019-2024 | Lifevest |
| Pfizer INC. | $186.38 | 2019-2025 | |
| Amgen INC. | $184.61 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $169.26 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $124.73 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $119.15 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $76.53 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $66.64 | 2019-2023 | Eliquis |
| Lundbeck LLC | $51.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.65 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $28.72 | 2021-2023 | Verquvo |
| Boston Scientific Corporation | $28.36 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.29 | 2019 | |
| Novo Nordisk INC | $16.91 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15.72 | 2019 | |
| Scpharmaceuticals INC. | $15.34 | 2023 | |
| Astellas Pharma US INC | $14.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.61 | 2019 | |
| Chiesi USA, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Zalkind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.